GATAD2A

Across TCGA pan-cancer cohorts, GATAD2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GATAD2A data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GATAD2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GATAD2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where GATAD2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.829	0.692	.003	12	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	10	view →
GBM	OS	Median	All	0.486	0.293	.019	2	view →
HNSC	DFS	Tertile	III,IV	0.525	0.795	.020	1	view →
LSCC	OS	Tertile	All	1.000	0.684	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GATAD2A–PDAC (DFS)

Open the PDAC breakdown →